Abstract - Research and Reports in Immunology (2021) Volume 4, Issue 5
Quadrivalent and nonavalent HPV vaccine: Ovarian safety research.
Human papillomavirus (HPV) vaccination may prevent up to 90% of oncogenic HPV infection. Quadrivalent and 9-valent vaccines and HPV testing are replacing the Papanicolaou cervical screening programme to reduce cervical cancer in Australia, which is now mostly confined to women not accessing regular screening. HPV vaccine marketing, licensing and advisory body statements of ovarian safety have followed case series of premature ovarian insufficiency (POI) in vaccine recipients.Author(s): Deirdre Little